Trial Details

TERMINATED
Basic Information
Clinical ID c1429
Identifier NCT03478956
Trial Title A Phase I Study of Etrolizumab Followed by Open-Label Extension and Safety Monitoring in Pediatric Patients With Moderate to Severe Ulcerative Colitis or Moderate to Severe Crohn's Disease
Trial URL Visit Original Page
Study Information
Study Results

YES

Conditions Ulcerative Colitis|Crohn's Disease
Interventions DRUG: Etrolizumab
Participant Information
Sponsor Hoffmann-La Roche
City Bruxelles
Country/Region Belgium
Enrollment Criteria
Sex Requirement ALL
Age Requirement CHILD
Study Design
Study Type INTERVENTIONAL
Phase PHASE1
Time Information
Start Date 2018-03-27
Primary Completion Date 2019-12-02
Completion Date 2023-09-27